Here are four points:
1. The collaboration will study the potential of combining EM Imaging’s in vivo optical imaging agents and Mauna Kea’s confocal laserendomicroscopy platform to diagnose cancer.
2. For the first study, EM Imaging will supply EMI-137, a clinical grade investigational molecular optical imaging agent, to two investigational sites to perform clinical efficacy studies with respect to pancreatic and lung cancers.
3. In the second project, EM Imaging will provide EMI-200, a neutrophil targeting optical molecular imaging agent, developed for topical administration in the lung.
4. Mauna Kea Technologies is a global medical device company focused on the accurate diagnosis and treatment of cancer using real-time in vivo microscopic visualization.
More articles on GI/endoscopy:
Gastroenterologist to know: Dr. Kulwinder Dua of the Medical College of Wisconsin
5 most read GI/endoscopy stories: April 4 – April 8
Dr. Douglas Pleskow co-authors book on Barrett’s esophagus: 4 points
